Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MDM4 | O15151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29855332 | 0.84 | FABP5 (0.40) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL2498935 | 0.80 | ALDH1A1 (0.40) | KMT2ACYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL118230 | 0.79 | FABP5 (0.46) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL29709499 | 0.79 | FABP5 (0.46) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL29908653 | 0.79 | FABP5 (0.46) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL27488088 | 0.77 | FABP5 (0.41) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL7951407 | 0.77 | SLC6A4 (0.40) | KMT2ACYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL25657461 | 0.75 | KMT2A (0.47) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL5171440 | 0.74 | FABP5 (0.38) | FABP5FABP7EPHX2MDM4TP53 | |
| SCHEMBL25185748 | 0.74 | FABP5 (0.42) | FABP5FABP7EPHX2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | FABP5 692/4885FABP7 215/4885EPHX2 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.